N/A N=206 Call for Life Youth ART Adherence Study
ART Adherence · HIV-1-infection · mHealth
Primary: • Viral Load Suppression — 61; 46 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=29 A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 0; 0; 1 Participants
Phase 1 N=64 A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events (AEs) — 12.5; 0.0; 16.7; 0.0 Percentage of participants
Phase 1 N=67 A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab — 215; 214; 293; 695 Microgram*…
N/A N=20 Immediate Placement and Stabilization of Dental Implants With Tetranite Stabilization Material in Mandibular and Maxillary Tooth Extraction Sites That Fail to Provide Adequate Primary Stability
Adhesive Dental
Primary: Implant Success (Modified Buser Criteria) — 6 participants
N/A N=274 Levonorgestrel Intrauterine System For Emergency Contraception
Pregnancy, Unplanned · Pregnancy; Accident
Primary: Number of Participants With Pregnancy Following Emergency Contraception — 0; 0; 0; 6 Participants
N/A N=41 Buprenorphine Treatment Engagement and Overdose Prevention
Opioid-use Disorder
Primary: Buprenorphine Treatment Adherence — 19.7; 16.1 percentage of urine samples — p=0.914
Phase 3 N=71 Phase 3 Study of SNF472 for Calciphylaxis
Calciphylaxis · Calcific Uremic Arteriolopathy
Primary: Absolute Change in the BWAT - CUA Score for the Primary Lesion — -5.3; -6.0 score on a scale — p=0.877
N/A N=40 Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
Tachycardia, Ventricular
Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants
Phase 4 N=5 Fibrinolytic Therapy Versus Medical Thoracoscopy
Pleural Diseases
Primary: Number of Hospital Days for Required to Treat Complicated Parapneumonic Effusions or Pleural Empyema. — 13; 18.5 days
Phase 2 N=63 Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
Osteopenia · Osteoporosis
Primary: Lumbar Spine Bone Mineral Content — 41.4; 38.7 Average grams
N/A N=156 An Economic and Relationship-strengthening Intervention for HIV-affected Couples Who Drink Alcohol in Malawi
HIV/AIDS · Alcohol Abuse
Primary: Enrollment Rate — 84 couples
N/A N=165 Acupuncture in the Emergency Department for Pain Management
Acupuncture · Pain Management · Emergency Department
Primary: Successful Recruitment of Participants Into the Study. — 26.1; 27.7; 16.3; 49.1 Percentage of participants enrolled
Phase 1 N=18 Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tepotinib — 18927; 23158 hours* nanograms per milliliter(h*ng/mL)
N/A N=65 Effects of Daily Supplementation of 5-HTP on Body Composition
Body Composition
Primary: Body Composition — 14.6; 12.6; 58.4; 57.7 Kilograms